Medicure Inc.

Equities

MPH

CA58469E4085

Biotechnology & Medical Research

Market Closed - Toronto S.E. 02:59:22 2024-04-26 pm EDT 5-day change 1st Jan Change
1 CAD -1.96% Intraday chart for Medicure Inc. -2.91% -28.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Medicure Inc., 2023 Earnings Call, Apr 09, 2024
Medicure Swung to a Loss in 2023 on Lower Sales MT
Medicure Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Marley Drug Announces A Partnership with TheracosBio to Distribute A Newly Approved Diabetes Drug, BRENZAVVY CI
Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease CI
Transcript : Medicure Inc., Q3 2023 Earnings Call, Nov 22, 2023
Medicure Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Medicure Inc., Q2 2023 Earnings Call, Jul 31, 2023
Medicure Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Medicure's Q1 Profit, Revenue Falls; Up Nearly 13% MT
Transcript : Medicure Inc., Q1 2023 Earnings Call, May 29, 2023
Medicure's Q1 Profit, Revenue Falls MT
Medicure Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Medicure Inc., Q4 2022 Earnings Call, Apr 10, 2023
Medicure Brief: Net income for Year ended December 31, 2022 was $1.4 million or $0.13 per share compared to a net loss of $727,000 or $0.07 per share for the year ended December 31, 2021 MT
Medicure Brief: Recorded total net revenue of $6.3 million during the quarter ended December 31, 2022 compared to $6.8 million for the quarter ended December 31, 2021 MT
Medicure Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors CI
Transcript : Medicure Inc., Q3 2022 Earnings Call, Nov 25, 2022
Medicure Reports Q3 2022 Net Income of $1.1 Million, Total Net Revenue of $5.3 Million MT
Medicure Brief: Net Income for the three months ended September 30, 2022 was $1.1 million or $0.11 per share; Recorded total net revenue of $5.3 million MT
Medicure Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Medicure Seeks Acquisitions CI
Transcript : Medicure Inc., Q2 2022 Earnings Call, Aug 25, 2022
Medicure Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Chart Medicure Inc.
More charts
Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
More about the company
  1. Stock Market
  2. Equities
  3. MPH Stock
  4. News Medicure Inc.
  5. Medicure's Q1 Profit, Revenue Falls; Up Nearly 13%